IRIS UniCatt

Bianco, Assunta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.102
EU - Europa 1.812
AS - Asia 1.702
SA - Sud America 344
AF - Africa 38
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.044
SG - Singapore 786
DE - Germania 666
CN - Cina 391
SE - Svezia 295
BR - Brasile 281
IT - Italia 208
VN - Vietnam 161
FR - Francia 155
GB - Regno Unito 104
UA - Ucraina 89
IE - Irlanda 71
IN - India 71
FI - Finlandia 64
HK - Hong Kong 54
ID - Indonesia 49
JP - Giappone 37
RU - Federazione Russa 29
CA - Canada 28
TR - Turchia 27
AR - Argentina 26
IQ - Iraq 24
PL - Polonia 23
BD - Bangladesh 22
AT - Austria 20
BE - Belgio 18
KR - Corea 15
NL - Olanda 15
CI - Costa d'Avorio 14
MX - Messico 14
VE - Venezuela 11
ES - Italia 9
SA - Arabia Saudita 9
IR - Iran 8
CO - Colombia 7
EC - Ecuador 7
IL - Israele 6
JO - Giordania 6
DO - Repubblica Dominicana 5
LT - Lituania 5
PK - Pakistan 5
TN - Tunisia 5
ZA - Sudafrica 5
AU - Australia 4
CZ - Repubblica Ceca 4
HU - Ungheria 4
MA - Marocco 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
UZ - Uzbekistan 4
CH - Svizzera 3
CL - Cile 3
NI - Nicaragua 3
NO - Norvegia 3
NP - Nepal 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
PS - Palestinian Territory 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GE - Georgia 1
HT - Haiti 1
JM - Giamaica 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
MY - Malesia 1
PG - Papua Nuova Guinea 1
PT - Portogallo 1
Totale 6.005
Salva come PNG Salva come JPEG
Città #
Singapore 448
Chandler 328
San Jose 248
Ashburn 202
Frankfurt am Main 125
Beijing 85
Ann Arbor 71
Dublin 71
New York 68
San Mateo 59
Jacksonville 57
Los Angeles 56
Hong Kong 53
Lauterbourg 51
Nürnberg 51
Hefei 50
Ho Chi Minh City 50
Jakarta 48
Hanoi 46
Milan 45
Rome 39
Tokyo 32
Boston 30
Munich 30
Nanjing 28
Wilmington 28
São Paulo 26
Princeton 25
Woodbridge 24
Dearborn 22
Helsinki 22
Chicago 20
Dallas 20
Moscow 20
Houston 19
Bremen 18
Marseille 18
Brussels 17
Nuremberg 17
Santa Clara 17
Atlanta 16
Buffalo 16
Kent 16
Warsaw 16
Pune 15
Seoul 15
Abidjan 14
Izmir 14
Lappeenranta 14
Orem 13
Turku 13
The Dalles 12
Baghdad 11
Brooklyn 11
London 11
Norwalk 11
Seattle 11
Cattolica 10
Council Bluffs 10
Lawrence 10
Rio de Janeiro 10
Vienna 10
Redwood City 9
Shanghai 9
Chennai 8
Denver 8
Düsseldorf 8
Haiphong 8
Leawood 8
North Bergen 8
Amsterdam 7
Boardman 7
Detroit 7
Kunming 7
Montreal 7
Nanchang 7
Paris 7
Thái Nguyên 7
Tianjin 7
Andover 6
Ankara 6
Da Nang 6
Falkenstein 6
Portsmouth 6
Toronto 6
Amman 5
Belo Horizonte 5
Changsha 5
Dhaka 5
Mexico City 5
Mountain View 5
Poplar 5
Rovato 5
San Francisco 5
Shenyang 5
Stockholm 5
University Park 5
Bexley 4
Caracas 4
Caxias do Sul 4
Totale 3.200
Salva come PNG Salva come JPEG
Nome #
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 264
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 253
CD8(+) T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI 238
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. 235
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 194
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 173
Lambert-Eaton Myasthenic Syndrome associated with gastric schwannoma 167
Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral 167
Demyelinating Encephalomyeloradiculitis with Balò-like lesions 163
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 163
New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report 148
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 147
Increased CD4(+)CD25(+)Foxp3(+) T Cells in Peripheral Blood of Celiac Disease Patients: Correlation with Dietary Treatment. 146
Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review 143
Epidemiology of intensive care unit-acquired sepsis in Italy: Results of the SPIN-UTI network 129
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 128
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients 127
Glioblastoma in multiple sclerosis: a case report 122
Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity 122
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 119
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 118
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 116
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 113
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review 112
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 110
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 110
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 110
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 106
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 104
Fingolimod vs dimethyl fumarate in multiple sclerosis 102
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies 95
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 94
Cyclophosphamide in highly aggressive Marburg-like multiple sclerosis 94
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 92
Acyclovir-related kidney injury during alemtuzumab infusion 86
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 86
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray) 83
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant? 82
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY) 77
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients 77
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 74
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 73
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of Frailty 69
Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved 69
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 66
A true isolated cognitive relapse in multiple sclerosis 66
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 63
An early feasibility study for neurological devices: The ARCTRAN study 60
Clinically relevant increases in serum neurofilament light chain and glial fibrillary acidic protein in patients with Susac syndrome 59
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w) 59
An early feasibility study for neurological devices: The ARCTRAN study 42
IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study 33
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study 27
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice 17
Paramagnetic Rim Lesions in Highly Active Multiple Sclerosis at the Time of Disease Diagnosis: Prevalence Data and Clinical Implications 10
Totale 6.102
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.918
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.918
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202161 0 0 0 0 0 0 0 0 0 0 56 5
2021/2022391 35 16 19 41 13 11 9 61 23 23 54 86
2022/2023878 91 110 61 139 65 116 43 84 100 10 43 16
2023/2024414 19 94 14 21 18 69 35 14 7 20 44 59
2024/2025833 14 25 63 53 45 33 17 26 140 73 188 156
2025/20262.457 325 67 126 250 495 220 430 154 171 202 17 0
Totale 6.102